Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Kallmann Syndrome

What is Kallmann Syndrome?

Kallmann syndrome is a rare disease characterized by the body’s failure to release proper growth and development hormones at the time of puberty. Both males and females with Kallmann syndrome will thus present only a few features of puberty, or in some cases will never start puberty. In males, certain features of sexual maturity that may not develop include the descent of testicles before birth, penile growth, body hair growth, increased muscle mass, and other characteristics. Females with Kallmann syndrome may develop little to no breast tissue, lack body hair growth, have poor growth in height, and may not develop a period. In addition to lack of sexual maturation, individuals with Kallmann syndrome may have other physical abnormalities such as cleft lip, short fingers and/or toes, deafness, and abnormal eye movement. It is also very common that individuals with Kallmann syndrome lack a sense of smell (anosmia). 

The human body’s growth and development is controlled by a series of chemicals known as hormones. In the instance of ​​sexual and reproductive maturation in humans, glands in the brain release hormones that trigger a response in male and female reproductive organs. The hypothalamus and pituitary glands located in the brain are responsible for producing the growth and maturation hormones and releasing them into the bloodstream. One such hormone, known as gonadotropin-releasing hormone (GnRH), is released by the hypothalamus at the onset of puberty. Specialized neuron cells, known as GnRH neurons, produce and release GnRH. GnRH stimulates the pituitary gland to produce luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Once released, LH and FSH act on the reproductive organs: in men, testosterone and sperm are produced by the testes, and in women, estrogen and eggs are produced in the ovaries. In cases of Kallmann syndrome, this process of hormone production, release, and delivery to the reproductive organs is disrupted and delays or prevents puberty. 

 

 

Synonyms

  • Hypogonadotropic hypogonadism
  • Anosmic hypogonadism
  • Olfacto-genital pathological sequence

Kallmann syndrome is a rare disease characterized by the body’s failure to release proper growth and development hormones at the time of puberty. Both males and females with Kallmann syndrome will thus present only a few features of puberty, or in some cases will never start puberty. In males, certain features of sexual maturity that may not develop include the descent of testicles before birth, penile growth, body hair growth, increased muscle mass, and other characteristics. Females with Kallmann syndrome may develop little to no breast tissue, lack body hair growth, have poor growth in height, and may not develop a period. In addition to lack of sexual maturation, individuals with Kallmann syndrome may have other physical abnormalities such as cleft lip, short fingers and/or toes, deafness, and abnormal eye movement. It is also very common that individuals with Kallmann syndrome lack a sense of smell (anosmia). 

The human body’s growth and development is controlled by a series of chemicals known as hormones. In the instance of ​​sexual and reproductive maturation in humans, glands in the brain release hormones that trigger a response in male and female reproductive organs. The hypothalamus and pituitary glands located in the brain are responsible for producing the growth and maturation hormones and releasing them into the bloodstream. One such hormone, known as gonadotropin-releasing hormone (GnRH), is released by the hypothalamus at the onset of puberty. Specialized neuron cells, known as GnRH neurons, produce and release GnRH. GnRH stimulates the pituitary gland to produce luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Once released, LH and FSH act on the reproductive organs: in men, testosterone and sperm are produced by the testes, and in women, estrogen and eggs are produced in the ovaries. In cases of Kallmann syndrome, this process of hormone production, release, and delivery to the reproductive organs is disrupted and delays or prevents puberty. 

 

Acknowledgement of Kallmann Syndrome has not been added yet.

Kallmann syndrome occurs in people of both genders. However, it is more common for men to seek medical advice and intervention when signs of puberty fail to appear. Thus, more cases of Kallmann syndrome have been recorded in men; about 1 in 30,000 males as opposed to about 1 in 120,000 females have been diagnosed with Kallmann syndrome, about 4 times as many men. While this rare disease usually causes symptoms that are life-long, about 10-15% of individuals with Kallmann syndrome have experienced spontaneous recovery of normal hormone levels during their lifetime. 

 

Name Abbreviation
Hypogonadotropic hypogonadism HH
Anosmic hypogonadism
Olfacto-genital pathological sequence

Kallmann syndrome is caused by a lack of gonadotropin-releasing hormone (GnRH), produced and released by specialized cells in the brain known as GnRH neurons. The development of GnRH neurons originates in the developing nose, and these cells migrate along the nasal passages involved in developing sense of smell, finally reaching the hypothalamus to be activated during puberty. Mutations in the development and migration of GnRH neurons is thus linked to development of olfactory neurons that enable a person’s sense of smell, and likely explains why so many individuals with Kallmann syndrome lack a sense of smell (anosmia). This is not always the case; in cases when the GnRH neurons migrate properly but possess mutations that inhibit release of GnRH hormones, the individual will experience Kallmann syndrome but retain their sense of smell. 

 

Some cases of Kallmann syndrome have been linked to genetic inheritance from the parents, and some present spontaneously without a known genetic cause. Human genes are located on condensed sequences of DNA known as chromosomes. Every person has 23 pairs of chromosomes, one inherited from each parent. Different genes can be located on one or more chromosomes, and every single cell nucleus contains every chromosome. Depending on the cell type, only certain genes within these chromosomes are expressed, meaning that the DNA is transcribed into mRNA that makes the proteins that the cell needs to grow and thrive. A person’s sex-linked characteristic genes are located on the twenty-third pair of chromosomes. In females, both of these chromosomes are the same size known as X chromosomes, while males have one X chromosome and one different Y chromosome. Thus, the Y chromosome can only be inherited from the father. In order to better understand the genetic cause of Kallmann syndrome mutations, a few common inheritance patterns are detailed below:

  1. Sex-linked inheritable traits can arise since the mother always provides an X chromosome to the offspring and the father provides either an X or a Y. If the mother carries a mutation on the X chromosome, it can either be compensated by the father’s donated X chromosome with a normal gene (female offspring) or become apparent in offspring if the father donates a Y chromosome (male offspring). 

  2. In autosomal dominant inherited disorders, a mutated gene need only be on one chromosome to have an effect on the offspring. This can be inherited from only one parent if they carry the mutated gene.

  3. In autosomal recessive inherited disorders, a mutated gene must be present on both paired chromosomes in order to exhibit a trait in the offspring. This means that both parents need to pass on their chromosome with a mutated gene to pass this trait to their children. 

  4. Oligogenic inherited disorders come from two or more different mutated genes must interact to cause a disease in the offspring. These genes may each have a mutation, one could have multiple mutations, and they combine in a way that affects the desired protein and its function in the cell. 

  5. Still other mutated genes may not come from the parents’ chromosomes, but may occur in offspring spontaneously during development and combination of genetic information. These are known as “de novo” mutations.

 

There are a number of genes that, when mutated, can lead to a lack of proper migration of GnRH neurons to the hypothalamus or, alternatively, affect the GnRH neurons’ ability to produce and release GnRH hormone. Genetic mutations that cause Kallmann syndrome associated with lack of smell (anosmia) impede GnRH cell migration during fetal development. These include Kal1, NELF, FGFR1, PROKR2, HS6ST1, CHD7, WDR11, SEMA3A. Alternatively, genes that do not affect GnRH cell migration but prevent release of GnRH hormone from these cells cause Kallmann syndrome without losing sense of smell. These genetic mutations include KISS1R, TACR3, GNRHR. Some genes can cause Kallmann syndrome with and without anosmia depending on the case: FGFR1, PROKR2, HS6ST1, CHD7, WDR11, SEMA3A. More details about the chromosome location, inheritance pattern, mutated protein, and resulting KS and/or anosmia symptoms are detailed in the table.

Gene

Location

Inheritance Pattern

Protein and Function

KS + Anosmia (Y/N)

CHD7

Chr8q12

Missense mutations (not inherited)

Chromodomain helicase DNA binding protein 7: causes CHARGE syndrome = eye shape irregularity, heart anomaly, nasal cavity narrowing, lack of growth and development, and genital and ear abnormalities

Y

FGF8/FGFR1

Chr8p11.2-p11.1

Autosomal dominant

Fibroblast growth factor receptor 1: FGF8 binds to FGFR1 to induce GnRH neuron migration

Y and N

GNRH1/GNRHR

Chr4q13.2

Autosomal recessive

Gonadotropin-releasing hormone and receptor: identify GnRH and lead to downstream signaling response

N

HS6ST1

Chr2q14.3

Oligogenic

Heparan sulfate 6-O-sulfotransferase: transfers sulfur in the signaling that develops neurons

Y

KAL1

Xp22.3

X-linked recessive

Anosmin-1: migration of GnRH and olfactory neurons

Y

KISS1R (GPR54)/KISS1

Chr19p13.3

Autosomal recessive

Kisspeptin receptor: recognizes kisspeptin that signals release of GnRH

N

NELF

Chr4p16.3

Oligogenic inheritance

Nasal embryonic LHRH factory gene: guides GnRH and olfactory neuron migration

Y

PROK2/PROKR2

Chr3p13

Oligogenicity

Prokineticin 2 and receptor: GnRH neuron development and release

Y

SEMA3A

Chr7q21.11

Mutation and deletion (not inherited)

Semaphorin 3A: provides cues to the neurons’ axons to grow during embryonic development

Y

TAC3/TACR3

Chr4q24

Autosomal recessive

Tachykinin signaling: activate “mini-puberty” and GnRH activation for puberty; GnRH deficiency may remedy in adulthood

N

WDR11

Chr10q26

Autosomal dominant

WD Repeat containing protein 11: unknown how this effects GnRH

Y

The primary symptoms experienced by individuals with Kallmann syndrome are a lack of hormones leading to fewer or no developments during puberty. Many individuals also experience lack of smell (anosmia) as detailed in the causes section due to the migratory pattern of the hormone releasing cells GnRH neurons. While both males and females are diagnosed with Kallman syndrome, their symptoms will present themselves in slightly different ways at puberty. Males diagnosed with Kallmann syndrome may have testicles that did not descend, decreased bone density and muscle mass leading to decline in growth, lack of penile growth (micropenis), erectile dysfuntion, low sex drive, and infertility. Females diagnosed with Kallmann syndrome will likely not start their menstrual period, have little to no development of breast tissue, and experience a similar lack of body hair and growth to their male counterparts. Some individuals may also experience symptoms such as facial abnormalities affecting the nose (anosmia), mouth (cleft palate), and eyes (abnormal movement or blindness), kidney problems (development of only one kidney), shortened fingers and/or toes, hearing loss, or color blindness. These latter symptoms are more rare, as symptoms generally present themselves at the onset of puberty. 

 

Many individuals diagnosed with Kallmann syndrome begin seeking medical advice or genetic counseling at or around puberty when they fail to exhibit common developmental characteristics. In males, this diagnosis may occur earlier if the testicles fail to descend or due to a smaller than average penis. Thus, Kallmann syndrome is 4 times more likely to be diagnosed in males than in females. 

 

Diagnostic tests for Kallmann syndrome focus primarily on determining the cause that the individual is not experiencing the characteristics of sexual development at puberty. There are a number of ways that individuals are evaluated:

  1. Physical examination - a doctor may examine the individual to for common developmental characteristics of puberty; failure to discern proper milestones may prompt further investigation 

  2. Tanner staging – method used by endocrinologists to evaluate proper maturation of primary and secondary sexual characteristics during puberty

  3. Hormonal evaluation – the hormones released by the hypothalamus and pituitary glands circulate in the blood and are delivered to the reproductive organs. Blood tests can measure levels of LH and FSH hormones compared to normal levels at puberty. The levels of sex hormones released as a result, testosterone and estrogen, can also be measured at diagnosis. GnRH is generally not measured, only the hormones released as a result of this signal are.

  4. Olfactory testing - the nasal cavity may be scanned by MRI to determine if lack of smell (anosmia) is due to Kallmann syndrome or physical blockage in the nasal cavity

  5. Genetic testing to confirm inheritance and subtype of KS: There are genetic tests available for mutations in KAL1,GNRHR, KISS1R, FGFR1, PROKR2, CHD7, and TACR3 genes are available to confirm the diagnosis. (http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab?db=GeneTests)

The primary treatment offered to individuals with Kallmann syndrome is the replacement or supplement of growth hormones that induce development of reproductive organs. Due to the lack of GnRH release, males may have decreased testosterone levels and females may have decreased estrogen levels. Hormone replacement therapy can be administered to induce sexual development. In males, testosterone is administered to signal the testes to produce sperm. In females, estrogen and progesterone are administered to signal to the ovaries to produce and release eggs to induce menstruation. This hormone supplementation must be tailored to the individual’s needs and adjusted after the onset of puberty for maintenance of growth and reproductive characteristics. 

 

Individuals with Kallmann syndrome should consider genetic and/or family counseling to seek advice from medical professionals about how to conceive despite a lack of reproductive signaling hormones. For individuals experiencing infertility as a result of Kallmann syndrome, pituitary hormones LH or FSH or even synthetic GnRH can be administered to increase fertility. Additionally, normal levels of hormones circulating in the bloodstream are associated with maintaining healthy bone density. Individuals with Kallmann syndrome may receive treatment for possible loss of bone density to avoid future complications such as osteoporosis.

 

Kallmann syndrome, while a life-long disease, is not life threatening and is treatable. Individuals with Kallmann syndrome experience delayed or lack of onset of puberty due to failure to release GnRH hormone. Hormone replacement therapy tailored to each individual’s needs can induce puberty and even reverse infertility, enabling the individual to reproduce normally. As therapy continues, different levels of hormones may need to be administered to meet the needs of the individual. If self-administered, such as in the case of testosterone or estrogen replacement, the individual may be able to work with their physician to determine which dose is appropriate. In the cases of LH and FSH replacement therapies or GnRH synthetic supplementation, individuals may need to regularly visit a clinic to receive injections. If left untreated, Kallmann syndrome prevents completion of puberty and causes infertility.

Genetic testing and counseling is available for many genetic disorders, including Kallmann syndrome: http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab?db=GeneTests

  1. https://rarediseases.info.nih.gov/diseases/10771/kallmann-syndrome 

  2. https://rarediseases.org/rare-diseases/kallmann-syndrome/

  3. https://www.rch.org.au/kidsinfo/fact_sheets/Kallmann_syndrome_an_overview/#:~:text=The%20condition%20is%20five%20times,with%20anosmia%2C%20or%20hypogonadotropic%20hypogonadism.

  4. https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=478

  5. Dodé, C., Levilliers, J., Dupont, JM. et al. Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet 33, 463–465 (2003). https://doi.org/10.1038/ng1122

  6. Legouis, R. et al. The candidate gene for the X-linked Kallmann syndrome encodes a protein related to adhesion molecules. Cell 67, (1991).

  7. Dodé, C. et al. Kallmann syndrome: Mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. PLoS Genet. 2, (2006).

My Brother Had This.... Created by TspineSryinx
Last updated 13 Oct 2014, 08:54 AM

Posted by TspineSryinx
13 Oct 2014, 08:54 AM

He did not know he had this until he was in his mid 20's. The doc looked at him and immediately diagnosed him just by looking at his face. No facial hair, baby face, very low energy, etc. The treatment changed his life for the better, thank God. If you have this, I just wanted to let you know that you can find help and it can be treated, at least from my brother's experience. Good luck and God Bless :)

Community Resources
Title Description Date Link

Clinical Trials


Cords registry

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, individuals and researchers to help in the advancement of research in over 7,000 rare diseases. The registry is free for patients to enroll and researchers to access.

Enrolling is easy.

  1. Complete the screening form.
  2. Review the informed consent.
  3. Answer the permission and data sharing questions.

After these steps, the enrollment process is complete. All other questions are voluntary. However, these questions are important to patients and their families to create awareness as well as to researchers to study rare diseases. This is why we ask our participants to update their information annually or anytime changes to their information occur.

Researchers can contact CoRDS to determine if the registry contains participants with the rare disease they are researching. If the researcher determines there is a sufficient number of participants or data on the rare disease of interest within the registry, the researcher can apply for access. Upon approval from the CoRDS Scientific Advisory Board, CoRDS staff will reach out to participants on behalf of the researcher. It is then up to the participant to determine if they would like to join the study.

Visit sanfordresearch.org/CoRDS to enroll.

Community Leaders

 

Expert Questions

Ask a question

Community User List

I am a patient with Kallmann syndrome. I was diagnosed at the age of 23 in the 1980's.

I talk to and meet as many fellow patients as I can and am active on patient networks to help try to raise...

My son just got diagnosed with Kallmann Syndrome
My name is George, I live in the state of Georgia and have kallma m syndrome and would like to know more people with same syndrome. Getting to know people with this disorder would help me a lot...

Start a Community


Don't See Your Condition On Rareshare?

Start your own! With a worldwide network of 8,000 users, you won't be the only member of your community for long.

FAQ


Have questions about rareshare?

Visit our Frequently Asked Questions page to find the answers to some of the most commonly asked questions.

Discussion Forum

My Brother Had This....

Created by TspineSryinx | Last updated 13 Oct 2014, 08:54 AM


Communities

Our Communities

Join Rareshare to meet other people that have been touched by rare diseases. Learn, engage, and grow with our communities.

FIND YOUR COMMUNITY
Physicians

Our Resources

Our rare disease resources include e-books and podcasts

VIEW OUR EBOOKS

LISTEN TO OUR PODCASTS

VIEW OUR GUIDES

Leaders

Our Community Leaders

Community leaders are active users that have been touched by the rare disease that they are a part of. Not only are they there to help facilitate conversations and provide new information that is relevant for the group, but they are there for you and to let you know you have a support system on Rareshare.